Seeking Alpha
0
All posts from Seeking Alpha
Seeking Alpha in Seeking Alpha - Read, Decide, Invest.,

Looking For Opportunity In Endo's Structural Changes

Revenue base in 2014

Endo International (NASDAQ: [[ENDP]]) is an Ireland-based company that manufactures and sells medicines. Lidoderm, Opana, Voltaren and Percocet contributed more than 943.5 mln USD in net sales during the first 9 months of 2013. Sales of those drugs for the first 9 months of 2014 decreased 48% to 489.4 mln USD. The main reason for such a rapid decrease is their direct competitor, Actavis, which launched several generics of Lidoderm and Opana. Opana is still the subject of lawsuits between Endo and Actavis, but if these lawsuits are unsuccessful Endo's revenue will continue to decline. Adjusted Income from continuing operations before income tax from U.S Branded Pharmaceuticals of Endo International for 9 months of 2014 decreased 38% to 395.4 mln USD for comparable 2013 period.

At the same time management took several big steps to avoid the crisis. The same adjusted income but from U.S. Generic… Read More …